文献速递淋巴瘤

莫妥珠单抗治疗既往≥2线治疗后复发或难治性滤泡性淋巴瘤的3年长期随访

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
PubMed 文献 · Blood · 2025-01-01

这项关键性1/2期研究在中位随访37.4个月时更新了90例既往≥2线治疗的复发/难治性滤泡性淋巴瘤患者接受固定疗程莫妥珠单抗的数据。研究者评估的完全缓解率为60.0%,客观缓解率为77.8%,中位缓解持续时间35.9个月,中位无进展生存期24.0个月,36个月总生存率82.4%。延长随访显示高缓解率、持久缓解和可控安全性,支持门诊使用莫妥珠单抗。

要点

  • 研究者评估的完全缓解率60.0%(95%CI 49.1-70.2),客观缓解率77.8%(95%CI 67.8-85.9)。
  • 70例缓解者中位缓解持续时间35.9个月(95%CI 20.7至不可估计)。
  • 36个月总生存率82.4%(95%CI 73.8-91.0),中位无进展生存期24.0个月(95%CI 12.0至不可估计)。

核心结论

  • 延长随访显示莫妥珠单抗在复发/难治性滤泡性淋巴瘤中具有高缓解率、持久缓解和可控的安全性,无长期担忧。
  • 作者认为这支持门诊使用莫妥珠单抗作为现成、固定疗程、安全有效的治疗,包括高危疾病患者。

研究设计与样本

  • 关键性1/2期研究,纳入90例既往≥2线治疗的复发/难治性滤泡性淋巴瘤患者,接受固定疗程莫妥珠单抗治疗。
  • 中位随访37.4个月,报告更新疗效和安全性数据。
  • 试验注册号NCT02500407。

主要发现

  • 研究者评估的完全缓解率为60.0%(95%CI 49.1-70.2),客观缓解率为77.8%(95%CI 67.8-85.9)。
  • 70例缓解者中位缓解持续时间为35.9个月(95%CI 20.7至不可估计)。
  • 54例达到完全缓解的患者中,49例在治疗结束时仍保持完全缓解;中位完全缓解持续时间未达到(95%CI 33.0至不可估计);Kaplan-Meier估计的30个月缓解率为72.4%(95%CI 59.2-85.6)。
  • 估计36个月总生存率为82.4%(95%CI 73.8-91.0),中位总生存未达到(95%CI 不可估计至不可估计);中位无进展生存期为24.0个月(95%CI 12.0至不可估计)。
  • 8周期莫妥珠单抗治疗后,CD19+ B细胞恢复的中位时间为18.4个月(95%CI 12.8-25.0);未报告新的细胞因子释放综合征事件或致命性、严重或≥3级不良事件。

临床怎么用

  • 作者认为这支持门诊使用莫妥珠单抗作为现成、固定疗程、安全有效的治疗,适用于复发/难治性滤泡性淋巴瘤患者,包括高危疾病患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mosunetuzumab, a CD20×CD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal phase 1/2 study after a median follow-up of 37.4 months in 90 patients with relapsed/refractory (R/R) follicular lymphoma (FL) and ≥2 prior lines of therapy treated with fixed-duration mosunetuzumab. Investigator-assessed complete response (CR) rate and objective response rate were 60.0% (95% confidence interval [CI], 49.1-70.2) and 77.8% (95% CI, 67.8-85.9), respectively. Among 70 responders, median duration of response was 35.9 months (95% CI, 20.7 to not estimable [NE]). Among 54 patients who achieved CR, 49 remained in CR at the end of treatment; median duration of CR was not reached (NR; 95% CI, 33.0 to NE); Kaplan-Meier-estimated 30-month remission rate was 72.4% (95% CI, 59.2-85.6). Estimated 36-month overall survival (OS) rate was 82.4% (95% CI, 73.8-91.0); median OS was NR (95% CI, NE to NE). Median progression-free survival was 24.0 months (95% CI, 12.0 to NE). Median time to CD19+ B-cell recovery was 18.4 months (95% CI, 12.8-25.0) after 8 cycles of mosunetuzumab treatment. No new cytokine release syndrome events or fatal, serious, or grade ≥3 adverse events were reported. With extended follow-up, mosunetuzumab demonstrated high response rates, durable remissions, and manageable safety with no long-term concerns. This supports outpatient mosunetuzumab administration as an off-the-shelf, fixed-duration, safe, and effective treatment for patients with R/R FL, including those with high-risk disease. This trial was registered at www.clinicaltrials.gov as #NCT02500407.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sehn LH, Bartlett NL, Matasar MJ, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood. 2025. PMID: 39447094. doi:10.1182/blood.2024025454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。